OSI Phase III Falls Short (OSIP, DNA)

Health and Healthcare

Published: October 6, 2008 7:47 am

Last Updated: April 28, 2020 3:19 am

OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning. The biotech has released data showing that a Phase III trial of Genentech’s (NYSE: DNA) Avastin combined with Tarceva in certain patients with advanced non-small-cell lung cancer did not meet the primary endpoint of increasing overall survival compared with Tarceva plus placebo.

The study assessed cancer patients who had progressed after goingthrough platinum based chemotherapy treatments. One note that thecompany made was that it did show evidence of clinical activity and itsaw improvements in secondary endpoints of progression-free survivaland response rate when Avastin was added to Tarceva compared to Tarcevaalone.

OSI Pharma is getting slammed in the early morning trading on analready tough morning for stocks. Shares are down 13% at $39.77 onabout 6,500 shares. Its 52-week trading range is $32.10 to $53.71.

Jon C. Ogg
October 6, 2008

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.